Cys-GM-CSF (17-31)
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | Cys-GM-CSF (17-31) |
| CAS NO. | / |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C76H133N28O25S |
| Molecular Weight | 1871.14g/mol |
| Purity (RP-HPLC) | ≥ 95.0% |
| Solubility | Soluble in water (≥ 5 mg/mL), dilute acetic acid, DMSO, and phosphate-buffered saline (PBS) |
| Endotoxin | ≤1.0 EU/mg |
| Biological Activity | Exhibits partial GM-CSF receptor binding activity; supports myeloid cell proliferation in vitro; EC₅₀ typically ≤ 50 nM in TF-1 cell assays |
| Storage Conditions | Store at -20°C to -80°C in a dry, dark, desiccated environment. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
Cys-GM-CSF (17-31) functions primarily as a partial agonist or receptor-binding modulator of the GM-CSF receptor (GM-CSFR), rather than a full mitogenic activator. This region (17-31) is part of the first α-helix and a critical receptor-binding domain of full-length GM-CSF. The peptide binds with low affinity to the alpha subunit of the GM-CSFR complex, potentially inducing sub-threshold signaling or acting as a competitive inhibitor against the full cytokine.
- Immunological Reagent Development: Conjugation of the peptide via the cysteine to carrier proteins (e.g., KLH, BSA) to generate specific antibodies against the GM-CSF receptor-binding region.
- Receptor Mapping & Interaction Studies: Use in competitive binding assays to map the epitope on GM-CSF that interacts with the GM-CSFR alpha chain, aiding in structure-function studies.
- Antagonist/Inhibitor Scaffold: Serving as a starting point for the design of peptide-based GM-CSF receptor antagonists to modulate inflammatory pathways.
- Surface Immobilization: Utilizing the thiol group for controlled orientation and immobilization on biosensor chips (e.g., for SPR) or microarray surfaces to study binding kinetics or screen for inhibitors.
- In VitroT-Cell Epitope Studies: Investigation of potential immunogenic or tolerogenic properties of this GM-CSF-derived sequence in immunological assays.
2.PRODUCT INDICATIONS
- Research Tool Efficacy: Its efficacy is defined by its successful use in generating specific immune reagents, mapping receptor interactions, and serving as a defined antigen in immunological studies.
- Therapeutic Target Context: The full-length GM-CSF is a clinically validated target. GM-CSF itself (sargramostim/Leukine®) is an FDA-approved drug to stimulate white blood cell production. Conversely, GM-CSF receptor antagonists (e.g., mavrilimumab) are under clinical investigation for autoimmune and inflammatory diseases like rheumatoid arthritis and COVID-19-associated hyperinflammation.
- Role in Drug Discovery: Peptide fragments like Cys-GM-CSF (17-31) are used in early-stage research to understand the precise binding interface between GM-CSF and its receptor. This knowledge is critical for the rational design of biologic inhibitors (monoclonal antibodies) or small-molecule modulators targeting this pathway.
- Clinical Status: This specific peptide fragment is not a drug candidate. Its value lies in enabling the preclinical research that informs the development of clinically relevant GM-CSF pathway modulators.
3.CLINICAL EFFICACY OF PRODUCT
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
